JP2018522049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522049A5 JP2018522049A5 JP2018505714A JP2018505714A JP2018522049A5 JP 2018522049 A5 JP2018522049 A5 JP 2018522049A5 JP 2018505714 A JP2018505714 A JP 2018505714A JP 2018505714 A JP2018505714 A JP 2018505714A JP 2018522049 A5 JP2018522049 A5 JP 2018522049A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrate
- pharmaceutically acceptable
- acceptable salt
- formula
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200556P | 2015-08-03 | 2015-08-03 | |
| US201562200545P | 2015-08-03 | 2015-08-03 | |
| US201562200549P | 2015-08-03 | 2015-08-03 | |
| US62/200,545 | 2015-08-03 | ||
| US62/200,549 | 2015-08-03 | ||
| US62/200,556 | 2015-08-03 | ||
| US201562201009P | 2015-08-04 | 2015-08-04 | |
| US62/201,009 | 2015-08-04 | ||
| US201562235102P | 2015-09-30 | 2015-09-30 | |
| US62/235,102 | 2015-09-30 | ||
| PCT/US2016/043676 WO2017023584A1 (en) | 2015-08-03 | 2016-07-22 | Combination therapies for treating cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020171578A Division JP2021001237A (ja) | 2015-08-03 | 2020-10-09 | がん処置のための組み合わせ療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522049A JP2018522049A (ja) | 2018-08-09 |
| JP2018522049A5 true JP2018522049A5 (cg-RX-API-DMAC7.html) | 2019-09-05 |
| JP6815383B2 JP6815383B2 (ja) | 2021-01-20 |
Family
ID=56555867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505714A Expired - Fee Related JP6815383B2 (ja) | 2015-08-03 | 2016-07-22 | がん処置のための組み合わせ療法 |
| JP2020171578A Pending JP2021001237A (ja) | 2015-08-03 | 2020-10-09 | がん処置のための組み合わせ療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020171578A Pending JP2021001237A (ja) | 2015-08-03 | 2020-10-09 | がん処置のための組み合わせ療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180207164A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3331531A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6815383B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016304172A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2994265A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1255939A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201717953A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017023584A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114522167A (zh) | 2018-07-31 | 2022-05-24 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| WO2020113216A1 (en) * | 2018-11-30 | 2020-06-04 | Aptose Biosciences Inc. | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
| US20230100235A1 (en) * | 2020-02-05 | 2023-03-30 | Carna Biosciences, Inc. | Anticancer agent composition |
| WO2024037910A1 (en) * | 2022-08-17 | 2024-02-22 | Institut National de la Santé et de la Recherche Médicale | Syk inhibitors for use in the treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1212240A1 (en) * | 2012-09-07 | 2016-06-10 | 吉宁特有限公司 | Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor |
| EP2983670A4 (en) * | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
| CA2914284A1 (en) * | 2013-05-30 | 2014-12-04 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| JP6478989B2 (ja) * | 2013-11-07 | 2019-03-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｃｄ２０抗体とｂｔｋ阻害剤とを用いた併用療法 |
| TWI735853B (zh) * | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| PL3179991T3 (pl) * | 2014-08-11 | 2022-02-14 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2 |
| TW201618775A (zh) * | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、ｐｄ－１抑制劑及／或ｐｄ－ｌ１抑制劑之治療組合物 |
| US20180353512A1 (en) * | 2015-06-23 | 2018-12-13 | Gilead Sciences, Inc. | Combination therapies for treating b-cell malignancies |
-
2016
- 2016-07-22 HK HK18115008.8A patent/HK1255939A1/zh unknown
- 2016-07-22 AU AU2016304172A patent/AU2016304172A1/en not_active Abandoned
- 2016-07-22 EP EP16745381.0A patent/EP3331531A1/en not_active Withdrawn
- 2016-07-22 WO PCT/US2016/043676 patent/WO2017023584A1/en not_active Ceased
- 2016-07-22 US US15/749,222 patent/US20180207164A1/en not_active Abandoned
- 2016-07-22 CA CA2994265A patent/CA2994265A1/en not_active Abandoned
- 2016-07-22 TW TW105123357A patent/TW201717953A/zh unknown
- 2016-07-22 JP JP2018505714A patent/JP6815383B2/ja not_active Expired - Fee Related
-
2020
- 2020-10-09 JP JP2020171578A patent/JP2021001237A/ja active Pending